As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year, the event continued to distinguish itself as a ...

European biotechs continue to face a demanding investment climate characterised by investor caution. As a result, many are ...

In 2025 alone, the agency issued over 50 oncology approvals [1], but the real story is the aggressive pivot toward targeted therapies for high-unmet-need solid tumors. That momentum has accelerated in ...

If you have been looking for Sector - Health funds, a place to start could be Fidelity Advisor Biotechnology A (FBTAX). FBTAX holds a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on ...

Holly Springs is being transformed by billions in life sciences investments expected to create thousands of high-paying jobs.

The US MFN healthcare policy aims to cap US prescription drug prices at the lowest price paid in other developed countries.

Harbor SMID Cap Core ETF returned 1.13% in Q4, trailing the Russell 2500 Index. View the full performance and sector ...

Mirador Therapeutics has raised $250M to advance clinical trials. Read about the Series B financing led by T. Rowe Price and ...

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

Danaher Corporation delivered slightly better-than-expected annual earnings, with conservative 2026 guidance that likely ...

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.

The Dallas-based genetics company and the UAE plan to store DNA from 100 of the most vulnerable species in a special lab in ...